Draft:Micro Labs Limited
Indian pharmaceutical company based in Bengaluru
From Wikipedia, the free encyclopedia
Micro Labs Limited is an Indian pharmaceutical company headquartered in Bengaluru, Karnataka. It was founded in 1973 by G. C. Surana and is currently managed by his sons Dilip Surana and Anand Surana. The company manufactures generic and branded formulations as well as active pharmaceutical ingredients (APIs), and exports to more than 50 countries.[1][2][3]
Submission declined on 12 November 2025 by Guninvalid (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: Multiple repeated citations, multiple self-cites, multiple citations specifically about Surana rather than the company, and multiple deleted drafts. This isn't necessarily irredeemable, but it might honestly be better to start from scratch. guninvalid (talk) 08:30, 12 November 2025 (UTC)
 | This is a draft article. It is a work in progress open to editing by anyone. Please ensure core content policies are met before publishing it as a live Wikipedia article. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL Last edited by Guninvalid (talk | contribs) 4 months ago. (Update)
Finished drafting? |
 | |
| Company type | Private |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1973 |
| Founder | G. C. Surana |
| Headquarters | |
Area served | Worldwide |
Key people | G. C. Surana (Founder) Dilip Surana (Chairman and Managing Director) Anand Surana (Joint Managing Director) |
| Products | Generic drugs, branded formulations, active pharmaceutical ingredients |
| Revenue | ₹5,300 crore (2023, approx.) |
Number of employees | 10,000+ |
| Website | microlabsltd.com |
History
Micro Labs began operations in 1973. Over time, it expanded its product portfolio to include medicines in therapeutic areas such as cardiology, diabetology, anti-infectives, and pain management. By the 2000s, it had established multiple facilities across India for both domestic and international supply.[4][5][6]
Products
The company manufactures a wide range of pharmaceuticals, including antibiotics, cardiovascular and antidiabetic drugs, and analgesics. Its most widely known brand is Dolo-650, a paracetamol formulation that saw extensive demand in India during the COVID-19 pandemic.[7][8][9]
Operations
Financials
As of the fiscal year ending 31 March 2024, Micro Labs Limited, the manufacturer of Dolo 650, reported revenues of approximately ₹6,670 crore.[13]In the previous year, credit rating agency CRISIL noted that the company’s revenue for FY 2023 was around ₹5,300 crore, driven by both domestic formulations and export growth.[14]
According to EMIS, the company has recorded consistent increases in key indicators such as operating profit, EBITDA, net profit, total assets, and equity in recent years.[15]The company also states in its corporate presentation that nearly 10 % of its revenue is derived from its Contract Research and Manufacturing Services (CRAMS) business.[16]
Controversies
In July 2022, the Income Tax Department conducted searches at Micro Labs' offices and promoters' residences across several states. Authorities alleged tax evasion of over ₹300 crore and the distribution of freebies to doctors valued at around ₹1,000 crore, practices which were considered violations of tax and ethical norms.[17][18][19]
See also
- Pharmaceutical industry in India
- Dolo-650
- provide significant coverage: discuss the subject in detail, not just brief mentions or routine announcements;
- are reliable: from reputable outlets with editorial oversight;
- are independent: not connected to the subject, such as interviews, press releases, the subject's own website, or sponsored content.
Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia.